Press Release May 14 2026
Filed with NSE · · 3 pages · English
Ref: Akums/Exchange/2026-27/10 May 14, 2026 Sub: Press Release Respected Sir/Madam, Dharamvir Malik Company Secretary & Compliance Officer Encl: As above Registered Office Akums reports Q4 FY26 and full year FY26 results with healthy top line and strong EBITDA growth; Board recommends dividend New Delhi, May 2026: Akums Drugs & Pharmaceuticals Ltd., India’s largest Contract Development and Manufac
Akums Drugs and Pharmaceuticals Limited on 6ix
In the deck
Earlier from Akums Drugs and Pharmaceuticals
- Akums Strengthens European and UK Presence -- India's Largest CDMO Expands Global Footprint
- Press Release Feb 13 2026
- Press Release Nov 13 2025
- Akums Receives ANVISA GMP Certification for Sterile Manufacturing Plant, Expands Global Sterile Manufacturing Footprint
- Press Release Aug 08 2025
Later from Akums Drugs and Pharmaceuticals
All Akums Drugs and Pharmaceuticals news releasesFollow Akums Drugs and Pharmaceuticals into a list and get an email when it puts out news.
Follow Akums Drugs and Pharmaceuticals